ProViZiGen is a biotherapeutics company developing the first of its kind injectable material capable of preventing and reversing osteoarthritis after joint injury.
Pictured (l. to r.): Co-founders Nada Haq-Siddiqi, Jin Montclare, and Julia Monkovic
Points of Differientiation
Current treatment for osteoarthritis involves pain management or total joint replacement. Our system, HydroGEN, delivers an injectable hydrogel that repairs injured tissue and prevents further degeneration, replacing the need for major surgery.
About ProViZiGen
Hear from ProViZiGen about their mission and what’s next on the horizon.Â
NYU Affiliation
Jin Montclare, Professor @ Tandon
Nada Haq-Siddiqi, Tandon Post-Doctoral Fellow
Julia Monkovic, Tandon M.S. ‘23
Contact Us
jkm318@nyu.edu
